<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360bbb–4" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360bbb–4/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360bbb–4/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360bbb_4"><akn:num>360bbb–4</akn:num><akn:heading>Countermeasure development, review, and technical assistance</akn:heading><akn:content><akn:p>§ 360bbb–4. Countermeasure development, review, and technical assistance(a) DefinitionsIn this section—(1) the term “countermeasure” means a qualified countermeasure, a security countermeasure, and a qualified pandemic or epidemic product;

(2) the term “qualified countermeasure” has the meaning given such term in section 247d–6a of title 42;

(3) the term “security countermeasure” has the meaning given such term in section 247d–6b of title 42; and

(4) the term “qualified pandemic or epidemic product” means a product that meets the definition given such term in section 247d–6d of title 42 and—(A) that has been identified by the Department of Health and Human Services or the Department of Defense as receiving funding directly related to addressing chemical, biological, radiological, or nuclear threats, including pandemic influenza; or

(B) is included under this paragraph pursuant to a determination by the Secretary.



(b) General dutiesIn order to accelerate the development, stockpiling, approval, licensure, and clearance of qualified countermeasures, security countermeasures, and qualified pandemic or epidemic products, the Secretary, in consultation with the Assistant Secretary for Preparedness and Response, shall—(1) ensure the appropriate involvement of Food and Drug Administration personnel in interagency activities related to countermeasure advanced research and development, consistent with sections 247d–6, 247d–6a, 247d–6b, 247d–6d, 247d–7e, and 300hh–10 of title 42;

(2) ensure the appropriate involvement and consultation of Food and Drug Administration personnel in any flexible manufacturing activities carried out under section 247d–7e of title 42, including with respect to meeting regulatory requirements set forth in this chapter;

(3) promote countermeasure expertise within the Food and Drug Administration by—(A) ensuring that Food and Drug Administration personnel involved in reviewing countermeasures for approval, licensure, or clearance are informed </akn:p></akn:content><akn:subsection eId="subsec_360bbb_4_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions In this section—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_b"><akn:num>(b)</akn:num><akn:heading>General duties</akn:heading><akn:content><akn:p>(b) General duties In order to accelerate the development, stockpiling, approval, licensure, and clearance of qualified countermeasures, security countermeasures, and qualified pandemic or epidemic products, the Secretary, in consultation with the Assistant Secretary for Preparedness and Response, shall—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_c"><akn:num>(c)</akn:num><akn:heading>Final guidance on development of animal models</akn:heading><akn:content><akn:p>(c) Final guidance on development of animal models</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_d"><akn:num>(d)</akn:num><akn:heading>Development and animal modeling procedures</akn:heading><akn:content><akn:p>(d) Development and animal modeling procedures</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_e"><akn:num>(e)</akn:num><akn:heading>Review and approval of countermeasures</akn:heading><akn:content><akn:p>(e) Review and approval of countermeasures</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_f"><akn:num>(f)</akn:num><akn:heading>Regulatory management plan</akn:heading><akn:content><akn:p>(f) Regulatory management plan</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_g"><akn:num>(g)</akn:num><akn:heading>Annual report</akn:heading><akn:content><akn:p>(g) Annual report Not later than 180 days after March 13, 2013, and annually thereafter, the Secretary shall make publicly available on the Web site of the Food and Drug Administration a report that details the countermeasure development and review activities of the Food and Drug Administration, including—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_h"><akn:num>(h)</akn:num><akn:heading>Accelerating countermeasure development and review during an emergency</akn:heading><akn:content><akn:p>(h) Accelerating countermeasure development and review during an emergency</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4_i"><akn:num>(i)</akn:num><akn:heading>Third party evaluation of tests used during an emergency</akn:heading><akn:content><akn:p>(i) Third party evaluation of tests used during an emergency</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>